このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Viridian Therapeutics 過去の業績

過去基準チェック /06

Viridian Therapeuticsの収益は年間平均-35.2%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間15.5% 33.7%割合で減少しています。

主要情報

-35.2%

収益成長率

31.7%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	-33.7%
株主資本利益率	-37.4%
ネット・マージン	-75,737.8%
前回の決算情報	31 Mar 2024

Recent updates

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Jun 12

Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?

May 28

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Sep 12

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

May 15

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Aug 22

Viridian Therapeutics Q2 2022 Earnings Preview

Aug 12

Viridian Therapeutics gets a new COO

Jun 23

Viridian Therapeutics (VRDN) Investor Presentation - Slideshow

Jun 08

収支内訳

Viridian Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:VRDN 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費
31 Mar 24	0	-218	88
31 Dec 23	0	-238	95
30 Sep 23	0	-217	72
30 Jun 23	1	-198	60
31 Mar 23	2	-172	49
31 Dec 22	2	-130	35
30 Sep 22	2	-113	32
30 Jun 22	1	-98	30
31 Mar 22	2	-87	28
31 Dec 21	3	-79	26
30 Sep 21	3	-141	24
30 Jun 21	3	-133	21
31 Mar 21	2	-121	17
31 Dec 20	1	-111	13
30 Sep 20	2	-30	10
30 Jun 20	3	-36	11
31 Mar 20	5	-38	11
31 Dec 19	4	-42	12
30 Sep 19	4	-42	12
30 Jun 19	4	-40	12
31 Mar 19	4	-40	11
31 Dec 18	8	-33	11
30 Sep 18	9	-29	11
30 Jun 18	10	-26	11
31 Mar 18	8	-24	11
31 Dec 17	4	-27	11
30 Sep 17	3	-26	11
30 Jun 17	3	-24	10
31 Mar 17	3	-21	9
31 Dec 16	3	-17	7
30 Sep 16	4	-17	5
31 Dec 15	5	-16	4
31 Dec 14	8	-6	4

質の高い収益: VRDNは現在利益が出ていません。

利益率の向上: VRDNは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: VRDNは利益が出ておらず、過去 5 年間で損失は年間35.2%の割合で増加しています。

成長の加速: VRDNの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: VRDNは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: VRDNは現在利益が出ていないため、自己資本利益率 ( -37.44% ) はマイナスです。

Viridian Therapeutics 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: EPS and revenues miss analyst expectations

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS and revenues miss analyst expectations

Recent updates

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?

Consensus revenue estimates increase by 21%

Price target decreased by 7.3% to US$36.50

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

New minor risk - Share price stability

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 15%, EPS upgraded

Price target decreased by 8.0% to US$40.07

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc. announced that it has received $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Price target decreased by 10% to US$41.36

Viridian Therapeutics, Inc. announced that it expects to receive $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Executive Changes

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates increase by 18%

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

President recently bought US$101k worth of stock

Consensus revenue estimates fall by 35%

President recently bought US$160k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Viridian Therapeutics, Inc. Appoints Scott Myers as Chief Executive Officer

Price target increased by 9.1% to US$47.08

Chief Medical Officer exercised options and sold US$708k worth of stock

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (Ted)

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Viridian Therapeutics Announces First Patient Enrolled in the ‘Thrive’ Phase 3 Trial in Patients with Thyroid Eye Disease

Consensus revenue estimates increase by 162%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new and inexperienced directors

Viridian Therapeutics, Inc Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Viridian Therapeutics, Inc. Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Viridian Therapeutics board compensation committee approves inducement grants

Consensus forecasts updated

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viridian Therapeutics, Inc. Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Price target increased to US$39.22

Viridian Therapeutics Q2 2022 Earnings Preview

Viridian Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

Viridian Therapeutics gets a new COO

Co-Founder notifies of intention to sell stock

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

CEO, President & Director notifies of intention to sell stock

Viridian Therapeutics, Inc. announced that it expects to receive $75 million in funding from Hercules Capital, Inc.

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

過去基準チェック /06